A prognostic model to predict outcome of patients failing to achieve pathological complete response after anthracycline-containing neoadjuvant chemotherapy for breast cancer

Journal of Surgical Oncology

Volumn 105, Issue 6, 2012, Pages 577-585

  Chen, Sheng ^a,b   Chen, Can Ming ^a,b   Yu, Ke Da ^a,b   Yang, Wen Tao ^a,b   Shao, Zhi Ming ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

breast cancer; DFS; neoadjuvant chemotherapy; OS; pathological complete response; prognostic factors

Indexed keywords

CATHEPSIN D; CYCLIN D1; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; KI 67 ANTIGEN; MULTIDRUG RESISTANCE PROTEIN; NAVELBINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; PROTEIN PS2; TAMOXIFEN;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INVASION; CANCER PATIENT; DRUG TREATMENT FAILURE; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATHOLOGICAL COMPLETE RESPONSE; PREDICTION; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CATHEPSIN D; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; KI-67 ANTIGEN; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE; YOUNG ADULT;

EID: 84859704103     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22140     Document Type: Article

References (31)

1. Hortobagyi GN,: Comprehensive management of locally advanced breast cancer. Cancer 1990; 66: 1387-1391.
2. Schwartz GF, Hortobagyi GN,: Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. Cancer 2004; 100: 2512-2532.
3. Fisher B, Bryant J, Wolmark N, et al.: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
4. Kuerer HM, Newman LA, Smith TL, et al.: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
5. Rastogi P, Anderson SJ, Bear HD, et al.: Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26: 778-785.
6. Rouzier R, Extra JM, Klijanienko J, et al.: Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002; 20: 1304-1310.
7. Rouzier R, Pusztai L, Delaloge S, et al.: Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 2005; 23: 8331-8339.
8. Guarneri V, Piacentini F, Ficarra G, et al.: A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. Ann Oncol 2009; 20: 1193-1198.
9. Symmans WF, Peintinger F, Hatzis C, et al.: Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007; 25: 4414-4422.
10. Colleoni M, Bagnardi V, Rotmensz N, et al.: A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer. Ann Oncol 2009; 20: 1178-1184.
11. Eisenhauer EA, Therasse P, Bogaerts J, et al.: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
12. Domagala W, Markiewski M, Harezga B, et al.: Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: Its relationship with vimentin and p53 protein. Clin Cancer Res 1996; 2: 147-154.
13. Penault-Llorca F, Cayre A, Bouchet Mishellany F, et al.: Induction chemotherapy for breast carcinoma: Predictive markers and relation with outcome. Int J Oncol 2003; 22: 1319-1325.
14. Pierga JY, Mouret E, Laurence V, et al.: Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. The role of clinical response. Eur J Cancer 2003; 39: 1089-1096.
15. Faneyte IF, Schrama JG, Peterse JL, et al.: Breast cancer response to neoadjuvant chemotherapy: Predictive markers and relation with outcome. Br J Cancer 2003; 88: 406-412.
16. Kuerer HM, Newman LA, Buzdar AU, et al.: Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 1998; 176: 502-509.
17. Machiavelli MR, Romero AO, Perez JE, et al.: Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998; 4: 125-131.
18. Gajdos C, Tartter PI, Estabrook A, et al.: Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol 2002; 80: 4-11.
19. Carey LA, Metzger R, Dees EC, et al.: American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 2005; 97: 1137-1142.
20. Botti C, Vici P, Lopez M, et al.: Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast. J Am Coll Surg 1995; 181: 202-208.
21. Cure H, Amat S, Penault-Llorca F, et al.: Prognostic value of residual node involvement in operable breast cancer after induction chemotherapy. Breast Cancer Res Treat 2002; 76: 37-45.
22. Jones RL, Salter J, A'Hern R, et al.: The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009; 116: 53-68.
23. Meric F, Mirza NQ, Buzdar AU, et al.: Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer. Ann Surg Oncol 2000; 7: 435-440.
24. Foekens JA, Look MP, Bolt-de Vries J, et al.: Cathepsin-D in primary breast cancer: Prognostic evaluation involving 2810 patients. Br J Cancer 1999; 79: 300-307.
25. Mazouni C, Romain S, Bonnier P, et al.: Prognostic significance of tumor-related proteases as a function of the estrogen receptor status. Cancer Biol Ther 2011; 11: 277-283.
26. Penault-Llorca F, Abrial C, Raoelfils I, et al.: Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 2008; 13: 1235-1245.
27. Vincent-Salomon A, Rousseau A, Jouve M, et al.: Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur J Cancer 2004; 40: 1502-1508.
28. Abrial SC, Penault-Llorca F, Delva R, et al.: High prognostic significance of residual disease after neoadjuvant chemotherapy: A retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 2005; 94: 255-263.
29. Petit T, Wilt M, Velten M, et al.: Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 2004; 40: 205-211.
30. MacGrogan G, Rudolph P, Mascarel Id I, et al.: DNA topoisomerase IIalpha expression and the response toprimary chemotherapy in breast cancer. Br J Cancer 2003; 89: 666-671.
31. Miyoshi Y, Kurosumi M, Kurebayashi J, et al.: Topoisomerase IIalpha-positive and BRCA1-negative phenotype: Association with favorable response to epirubicin-based regimens for human breast cancers. Cancer Lett 2008; 264: 44-53.